Literature DB >> 2211621

Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes.

M Kagimoto1, M Heim, K Kagimoto, T Zeugin, U A Meyer.   

Abstract

The debrisoquine/sparteine-type polymorphism is a clinically important inherited variation of drug metabolism characterized by two phenotypes, the extensive metabolizer and the poor metabolizer (PM). Five to 10 percent of individuals in Caucasian populations are of the PM phenotype and have deficient metabolism of debrisoquine and over 25 other drugs. Our previous studies have revealed absence of cytochrome P450IID6 protein and aberrant splicing of IID6 premRNA in livers of PMs. Moreover, two mutant alleles of the P450IID6 gene locus (CYP2D6) were identified by restriction fragment length analysis to be associated with the PM phenotype. However, the mutations of the CYP2D6 gene causing absent P450IID6 protein have not been defined. Here we report the cloning and sequencing of two types of mutant alleles of CYP2D6 isolated from genomic libraries of three PM individuals. One allele (29-A) was characterized by a single nucleotide deletion in the 5th exon with consequent frameshift and was observed in one individual only. The other type of mutant allele (29-B) was present in all three PM individuals and its sequence contained multiple mutations, notably four base changes causing amino acid changes in exons 1, 2 and 9, and a point mutation at the consensus sequence of the splice site of the 3rd intron. To understand the significance of the individual mutations, chimeric genes were constructed between the wild-type IID6 gene and the mutant 29-B allele or site-specific mutations were introduced into the IID6-cDNA and these DNA constructs were transiently expressed in COS-1 cells. The mutations in exon 1 resulted in a functionally deficient IID6 protein and the mutation at the splice site in absent IID6 protein, whereas the mutations in exons 2 and 9 were of no consequence for IID6 function. Only the mutation at the splice site thus explains the absence of P450IID6 protein in livers of PM individuals and appears to be a common cause of polymorphic drug oxidation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2211621

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  62 in total

1.  Detection of single base differences using biotinylated nucleotides with very long linker arms.

Authors:  K J Livak; F W Hobbs; R J Zagursky
Journal:  Nucleic Acids Res       Date:  1992-09-25       Impact factor: 16.971

Review 2.  Polymerase chain reaction and its potential as a pharmacokinetic tool.

Authors:  M H Heim
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

3.  Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers.

Authors:  T Graf; F Broly; F Hoffmann; M Probst; U A Meyer; H Howald
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 4.  mRNA transcript diversity creates new opportunities for pharmacological intervention.

Authors:  Elizabeth S Barrie; Ryan M Smith; Jonathan C Sanford; Wolfgang Sadee
Journal:  Mol Pharmacol       Date:  2012-02-07       Impact factor: 4.436

Review 5.  Polymorphic cytochromes P450 and drugs used in psychiatry.

Authors:  R T Coutts; L J Urichuk
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

6.  CYP2D6 genotype and phenotype determination in a Mexican Mestizo population.

Authors:  Marisol López; Jorge Guerrero; Helgi Jung-Cook; María Elisa Alonso
Journal:  Eur J Clin Pharmacol       Date:  2005-10-26       Impact factor: 2.953

7.  Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine.

Authors:  I Johansson; Q Y Yue; M L Dahl; M Heim; J Säwe; L Bertilsson; U A Meyer; F Sjöqvist; M Ingelman-Sundberg
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

8.  Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study.

Authors:  Yan Feng; Bruce G Pollock; Kim Coley; Stephen Marder; Del Miller; Margaret Kirshner; Manickam Aravagiri; Lon Schneider; Robert R Bies
Journal:  Br J Clin Pharmacol       Date:  2008-07-31       Impact factor: 4.335

Review 9.  Development and Uses of Offline and Web-Searchable Metabolism Databases - The Case of Benzo[a]pyrene.

Authors:  Slobodan P Rendic; Frederick P Guengerich
Journal:  Curr Drug Metab       Date:  2018       Impact factor: 3.731

Review 10.  Cytochrome P450 2D6.

Authors:  Ryan P Owen; Katrin Sangkuhl; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2009-07       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.